{"id":646,"date":"2025-05-22T13:56:02","date_gmt":"2025-05-22T11:56:02","guid":{"rendered":"https:\/\/cmyc.w.uib.no\/?page_id=646"},"modified":"2026-02-11T09:07:53","modified_gmt":"2026-02-11T08:07:53","slug":"clinical-research-studies","status":"publish","type":"page","link":"https:\/\/cmyc.w.uib.no\/nb\/research\/clinical-research-studies\/","title":{"rendered":"Kliniske forkninsstudier"},"content":{"rendered":"<p>These enrolling research studies are for patients with newly diagnosed AML.<\/p>\n\n\n\n<p>We differentiate the clinical trials according to the patient group they aim to include, from CML to fit, unfit and, residual AML.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">CML<\/h2>\n\n\n\n<h5 class=\"wp-block-heading\"><a href=\"https:\/\/cmyc.w.uib.no\/nb\/research\/clinical-research-studies\/kronisk-tretthet\/\" data-type=\"page\" data-id=\"1127\">Behandling av kronisk tretthet ved blodkreft<\/a><\/h5>\n\n\n\n<p>Pasienter med kronisk myelogen leukemi behandles med kinasehemmere, en tablettbehandling som resulterer i forventet overlevelse som friske. Samtidig rapporterer mange pasienter, s\u00e6rlig yngre kvinner, alvorlig kronisk tretthet (fatigue) og kognitive vansker som rammer arbeid, studier og familieliv. Denne studien vil unders\u00f8ke klinisk intervensjon i tre pasientgrupper:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>KML pasienter som har f\u00e5tt\/gjennomg\u00e5tt TKI-behandling i minst 3 m\u00e5neder.<\/li>\n\n\n\n<li>pasienter med myeloproliferativ neoplasi (MPN) uten behandling.<\/li>\n\n\n\n<li>pasienter med MPN som har gjennomg\u00e5tt allogen hematopoietisk stamcellebehandling for 6-9 m\u00e5neder siden.<\/li>\n<\/ul>\n\n\n\n<p><a href=\"https:\/\/cmyc.w.uib.no\/nb\/research\/clinical-research-studies\/kronisk-tretthet\/\" data-type=\"page\" data-id=\"1127\">Les mer om studien her.<\/a><\/p>\n\n\n\n<h2 class=\"wp-block-heading\">\n\t\tFIT AML\n\t<\/h2>\n\n\n\n<h5 class=\"wp-block-heading\">\n\t\tHOVON 501\n\t<\/h5>\n\n\n\n<p>Intensive chemotherapy in combination with venetoclax\/placebo.<\/p>\n\n\n\n<p>Unknown starting time<\/p>\n\n\n\n<p>Sites: Oslo universitetssykehus, Haukeland universitetssjukehus, Stavanger universitetssjukehus,&nbsp; Universitetssjukehuset i Nord Norge, Sankt Olavs Hospital<a href=\"https:\/\/hovon.nl\/en\/trials\/ho501-1\" target=\"_blank\" rel=\"noopener\">\n\t\t\t\t\t\tHOVON site\n\t\t\t\t\t<\/a><\/p>\n\n\n\n<h5 class=\"wp-block-heading\">\n\t\tQuantum-wild\n\t<\/h5>\n\n\n\n<p>For FLT3-ITD negative patients in combination with intensive chemotherapy and as maintenance.<\/p>\n\n\n\n<p>Starting Winter 2024\/2025<\/p>\n\n\n\n<p>Sites: UNN, OUS<a href=\"https:\/\/www.onclive.com\/view\/quantum-wild-trial-to-explore-correlative-outcomes-with-quizartinib-in-flt3-negative-aml\" target=\"_blank\" rel=\"noopener\">\n\t\t\t\t\t\tOnc Live\n\t\t\t\t\t<\/a><a href=\"https:\/\/ashpublications.org\/blood\/article\/144\/Supplement%201\/1504.3\/528973\/Trial-in-Progress-The-Phase-3-Randomized-Double\" target=\"_blank\" rel=\"noopener\">\n\t\t\t\t\t\tASH publication\n\t\t\t\t\t<\/a><a href=\"https:\/\/clinicaltrials.gov\/study\/NCT02039726\" target=\"_blank\" rel=\"noopener\">\n\t\t\t\t\t\tClinicalTrials.gov\n\t\t\t\t\t<\/a><\/p>\n\n\n\n<h2 class=\"wp-block-heading\">\n\t\tUn FIT AML\n\t<\/h2>\n\n\n\n<h4 class=\"wp-block-heading\">\n\t\t<a href=\"https:\/\/prosjektbanken.forskningsradet.no\/project\/FORISS\/303358\" title=\"Huvamer\" target=\"_blank\" rel=\"noopener\">\n\t\tHuvamer\n\t\t<\/a>\n\t<\/h4>\n\n\n\n<h5 class=\"wp-block-heading\">Repurposing in personalized leukemia therapy<\/h5>\n\n\n\n<p>Hydroxyurea + Valproat vs. 6-mercaptopurine + Valproat: newly diagnosted AML patients, not candidates for standard intensive treatment&nbsp; R\/R AML, high risk MDS<\/p>\n\n\n\n<p>Start time: ongoing<\/p>\n\n\n\n<p>Sites: Haukeland universitetssjukehus, Bj\u00f8rn Tore Gjertsen<a href=\"https:\/\/prosjektbanken.forskningsradet.no\/project\/FORISS\/303358\" target=\"_blank\" rel=\"noopener\">\n\t\t\t\t\t\tThe Research Council of Norway\n\t\t\t\t\t<\/a><a href=\"https:\/\/ctv.veeva.com\/study\/a-study-to-investigate-treatment-of-hu-and-vpa-or-6-mp-and-vpa-in-unfit-aml-hr-mds-patients\" target=\"_blank\" rel=\"noopener\">\n\t\t\t\t\t\tCTV\n\t\t\t\t\t<\/a><a href=\"https:\/\/www.helse-bergen.no\/kliniske-studier\/huvamer-studien\/\" target=\"_blank\" rel=\"noopener\">\n\t\t\t\t\t\tHelse Bergen information\n\t\t\t\t\t<\/a><\/p>\n\n\n\n<h5 class=\"wp-block-heading\">\n\t\tQC+VPA\n\t<\/h5>\n\n\n\n<p>Quinacrine;Mepacrine + Valproic acid; Orfiril Long depot caps.) off- label treatment outside a clinical study.<\/p>\n\n\n\n<p>&nbsp;R\/R AML patients with chronic infections unfit for other available treatment.<\/p>\n\n\n\n<p>Start time: ongoing<\/p>\n\n\n\n<p>Sites: Haukeland universitetssjukehus, Bj\u00f8rn Tore Gjertsen<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">\n\t\tResidual disease AML\n\t<\/h2>\n\n\n\n<h5 class=\"wp-block-heading\">\n\t\tIMPRESS\n\t<\/h5>\n\n\n\n<ol class=\"wp-block-list\">\n<li>IMPRESS: early KMML\/AML, MDS and AML high risk genetics<\/li>\n\n\n\n<li>IMPRESS AML MELFALAN: including AML\/MDS with low to normal ( up to 50%) cellularity,&nbsp; excluding patients with more than two cytogenetic aberrations or chromosome 7 aberrations, TP52 &gt;20%.<\/li>\n\n\n\n<li>IMPRESS AML ACTINOMYCIN D&nbsp; Including NPM1 mutated AML\/high risk MDS, exluding FLT3 mutation<\/li>\n<\/ol>\n\n\n\n<p>&nbsp;<\/p>\n\n\n\n<p>sites: Haukeland universitetssjukehus, Bj\u00f8rn Tore Gjertsen, XX Emil Nyquist.<a href=\"https:\/\/prosjektbanken.forskningsradet.no\/project\/FORISS\/328827?Kilde=FORISS&amp;distribution=Ar&amp;chart=bar&amp;calcType=funding&amp;Sprak=no&amp;sortBy=score&amp;sortOrder=desc&amp;resultCount=30&amp;offset=0&amp;Fritekst=IMPRESS\" target=\"_blank\" rel=\"noopener\">\n\t\t\t\t\t\tThe Research Council of Norway\n\t\t\t\t\t<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>These enrolling research studies are for patients with newly diagnosed AML. We differentiate the clinical trials according to the patient group they aim to include, from CML to fit, unfit <a class=\"read-more\" href=\"https:\/\/cmyc.w.uib.no\/nb\/research\/clinical-research-studies\/\">LES MER<\/a><\/p>","protected":false},"author":5388,"featured_media":0,"parent":2,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"ngg_post_thumbnail":0,"_EventAllDay":false,"_EventTimezone":"","_EventStartDate":"","_EventEndDate":"","_EventStartDateUTC":"","_EventEndDateUTC":"","_EventShowMap":false,"_EventShowMapLink":false,"_EventURL":"","_EventCost":"","_EventCostDescription":"","_EventCurrencySymbol":"","_EventCurrencyCode":"","_EventCurrencyPosition":"","_EventDateTimeSeparator":"","_EventTimeRangeSeparator":"","_EventOrganizerID":[],"_EventVenueID":[],"_OrganizerEmail":"","_OrganizerPhone":"","_OrganizerWebsite":"","_VenueAddress":"","_VenueCity":"","_VenueCountry":"","_VenueProvince":"","_VenueState":"","_VenueZip":"","_VenuePhone":"","_VenueURL":"","_VenueStateProvince":"","_VenueLat":"","_VenueLng":"","_VenueShowMap":false,"_VenueShowMapLink":false,"footnotes":""},"class_list":["post-646","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/cmyc.w.uib.no\/nb\/wp-json\/wp\/v2\/pages\/646","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cmyc.w.uib.no\/nb\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/cmyc.w.uib.no\/nb\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/cmyc.w.uib.no\/nb\/wp-json\/wp\/v2\/users\/5388"}],"replies":[{"embeddable":true,"href":"https:\/\/cmyc.w.uib.no\/nb\/wp-json\/wp\/v2\/comments?post=646"}],"version-history":[{"count":5,"href":"https:\/\/cmyc.w.uib.no\/nb\/wp-json\/wp\/v2\/pages\/646\/revisions"}],"predecessor-version":[{"id":1136,"href":"https:\/\/cmyc.w.uib.no\/nb\/wp-json\/wp\/v2\/pages\/646\/revisions\/1136"}],"up":[{"embeddable":true,"href":"https:\/\/cmyc.w.uib.no\/nb\/wp-json\/wp\/v2\/pages\/2"}],"wp:attachment":[{"href":"https:\/\/cmyc.w.uib.no\/nb\/wp-json\/wp\/v2\/media?parent=646"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}